search
Back to results

Electronic Capture of Adherence Barriers for HIV Care (CTNPT039)

Primary Purpose

HIV Infections

Status
Unknown status
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
The Opal patient portal and smartphone application combined with the I-Score patient-reported outcome measure
Sponsored by
McGill University Health Centre/Research Institute of the McGill University Health Centre
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for HIV Infections focused on measuring patient-reported outcomes, adherence, antiretroviral therapy, mHealth, smartphone app, patient portal, implementation science, care

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • be aged 18 years or older
  • be diagnosed with HIV-1 infection
  • be treated with a combination antiretroviral therapy (composed of 2 to 3 different drugs)
  • be treated for HIV at the Chronic Viral Illness Service of the McGill University Health Centre
  • be able to speak and understand either French or English
  • possess a smartphone
  • be willing to download the smartphone app

Exclusion Criteria:

  • are participating in a clinical trial at the time of enrollment in this study
  • have a cognitive impairment or medical instability that prevents them from participating in the interview
  • have insufficient mastery of French or English to participate in the interview and complete the questionnaires
  • have insufficient ability to use the app with the technical support provided
  • are co-infected with hepatitis C and are being treated for it or have completed treatment 3 months or less ago
  • are co-infected with hepatitis B and are either not treated for it or are being treated for it with a medication other than their anti-HIV medication

Sites / Locations

  • Research Institute of the McGill University Health Centre

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Opal patient portal

Arm Description

Exposure to routine use of a patient portal (Opal) through which HIV patients are expected to complete a measure on barriers to ART adherence for screening purposes, before each HIV care visit.

Outcomes

Primary Outcome Measures

Acceptability of the Intervention as assessed with the Acceptability E-scale
Score range: 6-30 (Threshold: M ≥ 24, indicates high acceptability)
Acceptability of the Intervention as indicated by the percent likely to recommend the I-Score
(Threshold: ≥ 80 percent)
Acceptability of the Intervention as assessed with the Net Promoter Score
Score range: -100 to 100 (Threshold: > 0, indicates acceptability)

Secondary Outcome Measures

Appropriateness of the Intervention as assessed with the Perceived Compatibility subscale
Score range: 1 to 7 (Threshold: Score M ≥ 5.5, indicates high compatibility)
Appropriateness of the Intervention as assessed with the Appropriateness of Intervention Measure
Score range: 1 to 5 (Threshold: Score M ≥ 4, indicates high appropriateness)
Feasibility of the Intervention as indicated by the consent rate
Reasons for refusal will also be collected (Threshold: ≥ 70 percent)
Feasibility of the Intervention as indicated by the retention rate
(Threshold: ≥ 80 percent)
Feasibility of the Intervention as indicated by the missing I-Score data rate
e.g., due to non-completion, network failure (Threshold: ≤ 10 percent)
Feasibility of the Intervention as assessed with the Feasibility of Intervention Measure
Score range: 1 to 5 (Threshold: M ≥ 4, indicates high feasibility)
Fidelity of the Intervention as indicated by the percentage of patients who complete the I-Score on time
(Threshold: ≥ 90 percent)
Fidelity of the Intervention as indicated by the percentage of physicians who review the I-Score results on time
(Threshold: ≥ 90 percent)
Feasibility of the implementation strategy as indicated by the percentage of physicians who participate in the implementation activities
e.g., educational meeting, focus groups (Threshold: ≥ 80 percent)
Feasibility of the implementation strategy as indicated by the number of technical issues encountered
Based on the Application Manager's notes

Full Information

First Posted
December 11, 2020
Last Updated
January 7, 2021
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborators
CIHR Canadian HIV Trials Network
search

1. Study Identification

Unique Protocol Identification Number
NCT04702412
Brief Title
Electronic Capture of Adherence Barriers for HIV Care
Acronym
CTNPT039
Official Title
Implementation of an Electronic Patient-reported Measure of Barriers to Antiretroviral Therapy Adherence With the Opal Patient Portal: a Mixed Method Type 3 Hybrid Pilot Study at a Large Montreal HIV Clinic
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Unknown status
Study Start Date
January 2021 (Anticipated)
Primary Completion Date
October 2021 (Anticipated)
Study Completion Date
January 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborators
CIHR Canadian HIV Trials Network

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Adherence to antiretroviral therapy (ART) remains problematic. Our team has thus developed a new patient-reported measure of barriers to ART adherence (the I-Score) which will be completed by HIV patients through the Opal patient portal for routine HIV care. This 6-month mixed method pilot study will implement the I-Score/Opal intervention with 5 HIV physicians at the McGill University Health Centre (Montreal, Quebec) and 30 of their patients. The study's primary objectives are to assess patient and physician perceptions of the intervention (e.g., acceptability) and evaluate the implementation strategy. The data collected will help plan and determine the feasibility of a definitive effectiveness trial.
Detailed Description
Background: Adherence to antiretroviral therapy (ART) remains problematic. Regular monitoring of its barriers is clinically recommended, however, patient-provider communication around adherence is often inadequate. Our team thus decided to develop a new electronically administered patient-reported outcome measure (PROM) of barriers to ART adherence (the I-Score) to facilitate the systematic capture of this data for physician consideration in routine HIV care. To prepare for a controlled definitive trial to test the I-Score intervention, a pilot study was designed. Its primary objectives are to evaluate patient and physician perceptions of the I-Score intervention and its implementation strategy. Methods: This one-arm, 6-month study will adopt a mixed method type 3 implementation-effectiveness hybrid design and be conducted at the Chronic Viral Illness Service of the McGill University Health Centre (Montreal, Canada). Five HIV physicians and 30 of their HIV patients with known or suspected adherence problems will participate. The intervention will involve having patients complete the I-Score in the Opal smartphone application, before meeting with their physician. Both patient and physician will have access to the I-Score results, for consideration during the clinic visits at Times 1, 2 (3 months), and 3 (6 months). The implementation strategy will focus on stakeholder involvement, education, and training; promoting the intervention's adaptability; and hiring an Application Manager to facilitate implementation. Implementation, patient, and service outcomes will be collected (Times 1-2-3). The primary outcome is the intervention's acceptability to patients and physicians. Qualitative data obtained, in part, through physician focus groups (Times 2-3) and patient interviews (Times 2-3) will help evaluate the implementation strategy and inform any methodological adaptations. Discussion: This study will help plan a definitive trial to test the efficacy of the I-Score intervention. It will generate needed data on electronic PROM interventions in routine HIV care that will help improve understanding of conditions for their successful implementation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
patient-reported outcomes, adherence, antiretroviral therapy, mHealth, smartphone app, patient portal, implementation science, care

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Pilot study with a mixed method type 3 implementation-effectiveness hybrid design
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Opal patient portal
Arm Type
Experimental
Arm Description
Exposure to routine use of a patient portal (Opal) through which HIV patients are expected to complete a measure on barriers to ART adherence for screening purposes, before each HIV care visit.
Intervention Type
Other
Intervention Name(s)
The Opal patient portal and smartphone application combined with the I-Score patient-reported outcome measure
Intervention Description
HIV patients will complete the I-Score PROM via Opal (patient portal) prior to three consecutive clinic visits with their HIV physician who is expected to access their PROM results in time for the visit. The clinic visits will be held at Time 1, Time 2 (3 months) and Time 3 (6 months).
Primary Outcome Measure Information:
Title
Acceptability of the Intervention as assessed with the Acceptability E-scale
Description
Score range: 6-30 (Threshold: M ≥ 24, indicates high acceptability)
Time Frame
Change from baseline (week 1) to study completion (week 24)
Title
Acceptability of the Intervention as indicated by the percent likely to recommend the I-Score
Description
(Threshold: ≥ 80 percent)
Time Frame
Change from baseline (week 1) to study completion (week 24)
Title
Acceptability of the Intervention as assessed with the Net Promoter Score
Description
Score range: -100 to 100 (Threshold: > 0, indicates acceptability)
Time Frame
Change from baseline (week 1) to study completion (week 24)
Secondary Outcome Measure Information:
Title
Appropriateness of the Intervention as assessed with the Perceived Compatibility subscale
Description
Score range: 1 to 7 (Threshold: Score M ≥ 5.5, indicates high compatibility)
Time Frame
Change from baseline (week 1) to study completion (week 24)
Title
Appropriateness of the Intervention as assessed with the Appropriateness of Intervention Measure
Description
Score range: 1 to 5 (Threshold: Score M ≥ 4, indicates high appropriateness)
Time Frame
Change from baseline (week 1) to study completion (week 24)
Title
Feasibility of the Intervention as indicated by the consent rate
Description
Reasons for refusal will also be collected (Threshold: ≥ 70 percent)
Time Frame
At baseline
Title
Feasibility of the Intervention as indicated by the retention rate
Description
(Threshold: ≥ 80 percent)
Time Frame
Cumulative until study completion (week 24)
Title
Feasibility of the Intervention as indicated by the missing I-Score data rate
Description
e.g., due to non-completion, network failure (Threshold: ≤ 10 percent)
Time Frame
Cumulative until study completion (week 24)
Title
Feasibility of the Intervention as assessed with the Feasibility of Intervention Measure
Description
Score range: 1 to 5 (Threshold: M ≥ 4, indicates high feasibility)
Time Frame
Change from baseline (week 1) to study completion (week 24)
Title
Fidelity of the Intervention as indicated by the percentage of patients who complete the I-Score on time
Description
(Threshold: ≥ 90 percent)
Time Frame
Cumulative until study completion (week 24)
Title
Fidelity of the Intervention as indicated by the percentage of physicians who review the I-Score results on time
Description
(Threshold: ≥ 90 percent)
Time Frame
Cumulative until study completion (week 24)
Title
Feasibility of the implementation strategy as indicated by the percentage of physicians who participate in the implementation activities
Description
e.g., educational meeting, focus groups (Threshold: ≥ 80 percent)
Time Frame
Cumulative until study completion (week 24)
Title
Feasibility of the implementation strategy as indicated by the number of technical issues encountered
Description
Based on the Application Manager's notes
Time Frame
Cumulative until study completion (week 24)
Other Pre-specified Outcome Measures:
Title
Patient management as indicated by the proportion of clinical visits where physicians took action based on I-Score results
Description
Only among visits that identified an adherence barrier of concern with the I-Score PROM
Time Frame
Change from baseline (week 1) to study completion (week 24)
Title
Barriers to ART adherence as measured by the I-Score PROM
Description
Score range: 1 to 20, where higher scores indicate a greater number of problematic barriers
Time Frame
Change from baseline (week 1) to study completion (week 24)
Title
Adherence to ART as measured by the Self-Rating Scale Item
Description
Score range: 1 to 6, where higher scores indicate higher adherence
Time Frame
Change from baseline (week 1) to study completion (week 24)
Title
HIV RNA viral load as indicated in the patient's medical file
Description
Range: Detectable, where > 50 copies/mL = detectable, an undesirable clinical outcome, or Undetectable
Time Frame
Change betweem baseline (week 1) and study completion (week 24)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: be aged 18 years or older be diagnosed with HIV-1 infection be treated with a combination antiretroviral therapy (composed of 2 to 3 different drugs) be treated for HIV at the Chronic Viral Illness Service of the McGill University Health Centre be able to speak and understand either French or English possess a smartphone be willing to download the smartphone app Exclusion Criteria: are participating in a clinical trial at the time of enrollment in this study have a cognitive impairment or medical instability that prevents them from participating in the interview have insufficient mastery of French or English to participate in the interview and complete the questionnaires have insufficient ability to use the app with the technical support provided are co-infected with hepatitis C and are being treated for it or have completed treatment 3 months or less ago are co-infected with hepatitis B and are either not treated for it or are being treated for it with a medication other than their anti-HIV medication
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bertrand Lebouché, MD
Phone
514-843-2090
Email
bertrand.lebouche@mcgill.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Kim Engler, PhD
Phone
514-934-1934
Ext
32126
Email
kimcengler@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bertrand Lebouché, MD
Organizational Affiliation
McGill University Health Centre/Research Institute of the McGill University Health Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
Research Institute of the McGill University Health Centre
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H4A3T2
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31376275
Citation
Engler K, Ahmed S, Lessard D, Vicente S, Lebouche B. Assessing the Content Validity of a New Patient-Reported Measure of Barriers to Antiretroviral Therapy Adherence for Electronic Administration in Routine HIV Care: Proposal for a Web-Based Delphi Study. JMIR Res Protoc. 2019 Aug 2;8(8):e12836. doi: 10.2196/12836.
Results Reference
background
PubMed Identifier
30375111
Citation
Lessard D, Engler K, Toupin I; I-Score Consulting Team; Routy JP, Lebouche B. Evaluation of a project to engage patients in the development of a patient-reported measure for HIV care (the I-Score Study). Health Expect. 2019 Apr;22(2):209-225. doi: 10.1111/hex.12845. Epub 2018 Oct 29.
Results Reference
background
PubMed Identifier
30741643
Citation
Kildea J, Battista J, Cabral B, Hendren L, Herrera D, Hijal T, Joseph A. Design and Development of a Person-Centered Patient Portal Using Participatory Stakeholder Co-Design. J Med Internet Res. 2019 Feb 11;21(2):e11371. doi: 10.2196/11371.
Results Reference
background
PubMed Identifier
34969046
Citation
Engler K, Vicente S, Ma Y, Hijal T, Cox J, Ahmed S, Klein M, Achiche S, Pant Pai N, de Pokomandy A, Lacombe K, Lebouche B. Implementation of an electronic patient-reported measure of barriers to antiretroviral therapy adherence with the Opal patient portal: Protocol for a mixed method type 3 hybrid pilot study at a large Montreal HIV clinic. PLoS One. 2021 Dec 30;16(12):e0261006. doi: 10.1371/journal.pone.0261006. eCollection 2021.
Results Reference
derived

Learn more about this trial

Electronic Capture of Adherence Barriers for HIV Care

We'll reach out to this number within 24 hrs